You searched for "training"

832 results found

The PROMIS trial – time for multi-parametric MRI before a first prostate biopsy

Whilst the relatively random process of 12 core transrectal ultrasound guided (TRUS) prostate biopsy remains by far the most widely employed approach to prostate cancer diagnosis in the UK, its flaws as a standalone diagnostic strategy are increasingly apparent. TRUS-biopsy...

Bridging the gap – a nurse-led UTI information and support service

Urinary tract infections (UTIs) are among the most frequently diagnosed bacterial infections in both primary and secondary care. While acute, uncomplicated cases may be managed effectively, recurrent and chronic UTIs often present a more complex challenge. For many people, these...

Action Bladder Cancer UK launches learning module for primary care

Action Bladder Cancer UK has launched a new online learning module for primary care, to help healthcare professionals improve their knowledge of bladder cancer. Bladder cancer is not a rare cancer. In the UK alone, over 23,000 people are diagnosed...

Bladder cancer: where are we with intravesical therapies?

In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...

Ambulatory local anaesthetic implantation of percutaneous sacral nerve stimulators

Background The current treatment paradigm for detrusor overactivity (DO) and dysfunctional voiding (DV) includes conservative measures, pharmacotherapy, intravesical onabotulinum toxin A (Botox®), sacral nerve modulation (SNM / SNS) and urinary diversion as a last resort [1]. Incidence of DO is...

A Revolution in your hands: Wellspect launch innovative new female catheter

Wellspect have been innovators in catheterisation since developing the world’s first hydrophilic catheter. Now the Swedish company look to revolutionise the way women learn and perform intermittent self-catheterisation (ISC).

Urological trauma – part 1

Part 2 of this topic is available here. Case 1 A 45-year-old male presented with acute onset abdominal pain following a fall whilst out drinking. A CT cystogram was arranged as he developed haematuria and acute renal impairment. 1. What...

New ultrasound imaging technique reliably spots prostate cancer, initial patient trial reveals

A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...

Prostate Scotland launches updated resource to support men considering active surveillance for early prostate cancer

Prostate Scotland has launched an updated patient information booklet focusing on active surveillance. The resource is designed for men newly diagnosed with localised prostate cancer, helping them to understand active surveillance as a management option and supporting informed discussions with...

Millions of women in their 40s are SUFFERING with bladder leakage

Two thirds of women over 40 are currently SUFFERING with bladder leakage – with many feeling EMBARRASSED and DEPRESSED as a direct result, a study found. The condition, which can be caused by childbirth and often develops as women get older, is believed to affect MILLIONS of females - of all ages.

Defining adjuvant, consolidative, and salvage treatment after RP

The most common oncologic outcome following radical prostatectomy (RP) for localised prostate cancer is achieving undetectable prostate-specific antigen (PSA) levels (<0.1 ng/ml), indicating an absence of detectable disease. However, the landscape of RP is shifting as active surveillance becomes the...